Arkolith/Insider Trading/APTO/Form 4

Rice William G.

Chair, President & CEO, DirectorAptose Biosciences Inc. (APTO) · full profile →Form 4 · filed Jul 1, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
13
1 non-derivative · 12 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 30, 2026Disposed to issuer(D)613K$1.72$1.1M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 30, 2026Disposed to issuer(D)70K—$00
Jun 30, 2026Disposed to issuer(D)50K—$00
Jun 30, 2026Disposed to issuer(D)400K—$00
Jun 30, 2026Disposed to issuer(D)600K—$00
Jun 30, 2026Disposed to issuer(D)700K—$00
Jun 30, 2026Disposed to issuer(D)343K—$00
Jun 30, 2026Disposed to issuer(D)2.0M—$00
Jun 30, 2026Disposed to issuer(D)400K—$00
Jun 30, 2026Disposed to issuer(D)100K—$00
Jun 30, 2026Disposed to issuer(D)50K—$00
Jun 30, 2026Disposed to issuer(D)300K—$00
Jun 30, 2026Disposed to issuer(D)400K—$00

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000912282-26-000897) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML